Navigation Links
Curemark Appoints Jennifer Katritos, CPA as Vice President of Finance

RYE, N.Y., Dec. 13, 2010 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, has appointed Jennifer Katritos, CPA, as vice president of finance, the company announced.  She joined Curemark in July, 2009 as director of finance.  Katritos oversees Curemark's financial function, responsible for financial planning and reporting and risk analysis.

During her 20-year career, Katritos has held a variety of financial positions, primarily in the research-focused nonprofit sector.  Prior to Curemark, she served as director of finance for the Multiple Myeloma Research Foundation and the Multiple Myeloma Research Consortium.  Previously, Katritos headed her own financial consulting practice with a focus on nonprofit and emerging businesses.

"We are extremely pleased about Jennifer's well-deserved and well-earned promotion," said Joan Fallon, Curemark founder and CEO.  "She came to Curemark with a stellar financial background and extensive experience in the research space.  She has exhibited strong leadership in the financial arena."  

"It has been incredibly rewarding to utilize my financial expertise in a way that helps individuals in need.  I am particularly thrilled to be working with Joan and the Curemark team," Katritos said.  "I am inspired by their dedication to help children and families with the pervasive issue of autism."

Katritos began her career with Deloitte and Touche LLP in New York.  She holds a BS in Accounting and Finance from the State University of New York at Oneonta.

Curemark is currently in Phase III clinical trials for CM-AT, an autism treatment which has received Fast Track status from the FDA.


Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
(Date:12/1/2015)... 1, 2015  AccuTEC Blades, a leader in ... logo and brand identity program. The new logo ... of bladed products where "the edge makes all ... --> Serving manufacturers and distributors of medical, ... equipment, AccuTEC,s product lines include those acquired when ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Trustify is proud to announce the success ... Becky’s Fund, an organization dedicated to ending domestic violence. , Trustify and Becky’s Fund ... victims and survivors of domestic violence. Trustify is also proud to announce the launch ...
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , ... a container patent that allows for easier packing and organizing of items into one ... $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services ... Jordan Industries International, LLC (“JII”). , With support from JII, Integrated Rental is ... to hospitals, surgery centers, clinics, research labs and medical facilities across the United ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... of leadless pacemakers in the U.S. and is the only hospital in the ... the largest clinical data presentation of transcatheter pacing patients were revealed recently at ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation claim ... of hospital and nonhospital care, according to a recent study by the Workers Compensation ... Edition , found medical payments per claim with more than seven days of lost ...
Breaking Medicine News(10 mins):